Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Capecitabine in Advanced Pancreatic Cancer
NCT02117479Phase 3Terminated
- Sponsor
- Incyte
- Start
- Mar 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of ruxolitinib in pancreatic cancer (PC), sponsored by Incyte. Started Mar 2014; status: terminated.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02117479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02117479.